Dear The role of semaglutide in the treatment and progression of non-alcoholic fatty liver disease
DOI:
https://doi.org/10.36557/2674-8169.2024v6n6p2132-2142Keywords:
Semaglutida, Tratamento, Esteatose Hepática, Doença Hepática Gordurosa Não Alcoólica (DHGNA).Abstract
The integrative review aimed to assess the efficacy and safety of semaglutide treatment in managing non-alcoholic fatty liver disease (NAFLD), addressing its impact on non-alcoholic steatohepatitis across different patient populations. Initially, 187 studies were retrieved, of which 145 were excluded for not meeting specific inclusion criteria. Following a more detailed evaluation, 5 studies were selected and included in the review. Results highlight the pleiotropic effects of semaglutide, demonstrating improvements in NASLD markers and significant reduction in cardiovascular risks. Studies in human patients showed glycemic control and weight reduction, while animal model studies revealed improvements in liver function and lipid composition. Research by Soto-Catalán et al. suggested that the effects of semaglutide may directly affect the liver, irrespective of food intake, providing a complementary perspective to human studies. The importance of these findings in clinical management of NAFLD is underscored, pointing to the need for further research to further elucidate the therapeutic effects of semaglutide in this condition.
Downloads
References
Barritt AS et al. Review Article: The Role of Glucagon-Like Peptide-1 Receptor Agonists in Non-Alcoholic Steatohepatitis, Obesity, and Diabetes - What Hepatologists Need to Know. Aliment Pharmacol Ther. 2022; 55(8): 944-959.
Carretero-Gómez J et al. Diabetes, Obesity, and Nutrition Working Group of the Spanish Society of Internal Medicine (SEMI): Effect of Semaglutide on Biomarkers of Fatty Liver Disease in Patients with Diabetes and Obesity. Rev Clin Esp (Barc). 2023; 223(3): 134-143.
Hachuła M, et al. Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes-Interventional Study. Pharmaceuticals (Basel). 2023; 16(9):1190.
Htike ZZ, et al. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Obes Metab. 2017; 19(4): 524-536.
Liu C, et al. Increased Visceral Fat Area Relative to Skeletal Muscle Mass is Positively Associated with the Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Chinese Population. Lipids Health Dis. 2024; 23(1): 104.
Seijas-Amigo J, et al. Semaglutida versus agonistas GLP-1. Efectividad, seguridad y calidad de vida en pacientes con diabetes mellitus 2. Estudio VÁRIOS. Farm Hosp. 2022; 46(6): 372-379.
Soto-Catalán M, et al. Semaglutide Improves Hepatic Steatosis and De Novo Lipogenesis Markers in Obese and Type 2 Diabetic Mice with Metabolic Dysfunction-Associated Steatotic Liver Disease. Int J Mol Sci. 2024; 25(5):2961.
Staufer K, Stauber RE. Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?. Biomedicines. 2023; 11(8): 2108.
Volpe S, et al. Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Study. Nutrientes. 2022; 14(21): 4673.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Luciana Mami Kiam, Anna Luysa de Sousa Moura, Maria Clara Petinati B. da Rocha, Renato Júnior dos Reis Aguiar, Ana Leticia Rabelo de Araujo, Bruna de Lazary Castro, Brisa da Silva Lopes, Leticia Alves Santos, Júlia Valena Paiva da Fonseca, Victor Martins Farias, Barbara Antonia Dups Talah, Isabela Carvalho Gobbi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors are copyright holders under a CCBY 4.0 license.
